Ensysce Biosciences (NASDAQ:ENSC) Stock Rating Upgraded by Wall Street Zen

Ensysce Biosciences (NASDAQ:ENSC) was upgraded by investment analysts at Wall Street Zen to a “hold” rating in a research report issued to clients and investors on Saturday.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Ensysce Biosciences in a research report on Wednesday, October 8th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Sell”.

Ensysce Biosciences Stock Performance

Ensysce Biosciences stock opened at $2.23 on Friday. The firm’s fifty day moving average price is $2.22 and its 200-day moving average price is $2.23. The stock has a market cap of $6.62 million, a P/E ratio of -0.55 and a beta of 1.10. Ensysce Biosciences has a fifty-two week low of $1.62 and a fifty-two week high of $14.67.

Ensysce Biosciences (NASDAQ:ENSC) last announced its earnings results on Wednesday, August 13th. The company reported ($0.79) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.02) by $0.23. Ensysce Biosciences had a negative net margin of 88.76% and a negative return on equity of 167.23%. The firm had revenue of $1.37 million for the quarter, compared to analyst estimates of $0.67 million. On average, analysts predict that Ensysce Biosciences will post -8.33 earnings per share for the current year.

Institutional Investors Weigh In On Ensysce Biosciences

Several institutional investors have recently made changes to their positions in the company. TRU Independence Asset Management 2 LLC bought a new stake in shares of Ensysce Biosciences in the 3rd quarter worth about $25,000. Adage Capital Partners GP L.L.C. lifted its holdings in shares of Ensysce Biosciences by 49.4% in the 1st quarter. Adage Capital Partners GP L.L.C. now owns 74,711 shares of the company’s stock worth $191,000 after acquiring an additional 24,711 shares during the last quarter. Finally, Murchinson Ltd. bought a new stake in shares of Ensysce Biosciences in the 1st quarter worth about $358,000. Institutional investors own 5.63% of the company’s stock.

Ensysce Biosciences Company Profile

Ensysce Biosciences, Inc, a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology.